Alkermes disclosed early Phase 1 randomized data suggesting its orexin agonist ALKS 7290 may treat attention-deficit/hyperactivity disorder (ADHD). The company reported the drug was well tolerated and showed a signal of efficacy in adults with moderate-to-severe symptoms, with higher-dose patients seeing symptom reductions on the Adult ADHD Investigator Symptom Rating Scale. The data extend orexin agonist development beyond sleep disorders and into a broader neuropsychiatric indication set. While Phase 1 findings are not confirmatory, they provide dose-selection and translational justification for later-stage trials. For biotech decision-makers, the key question now is whether the early biomarker-and-symptom separation holds in larger studies and whether orexin engagement translates into durable, clinically meaningful improvement.